Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Conor to expand pivotal DES (drug-eluting stent) trial:

This article was originally published in Clinica

Executive Summary

The US FDA has given Conor Medsystems approval to expand enrolment in its pivotal drug-eluting stent (DES) trial to the full cohort of 1,700 patients at up to 85 sites. The COSTAR II trial, in which the first patient was enrolled in May 2005, is comparing the firm's cobalt chromium paclitaxel-eluting stent, CoStar, with Boston Scientific's market-leading DES, Taxus. The devices are being used to treat de novo lesions in patients with single or multi-vessel coronary artery disease. The study's primary endpoint is major adverse cardiac events (MACE) at eight months. The Menlo Park, California firm expects to use the trial's data to support a US marketing application for CoStar.

Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT058164

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel